Navigation Links
Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 /PRNewswire-FirstCall/ -- Baxter International Inc. today announced final Phase I/II data for its adjuvant-free investigational pandemic H5N1 influenza vaccine and plans to initiate a Phase III clinical trial of the candidate vaccine in Europe to confirm the study results.

The Phase I/II study indicated that Baxter's H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains. The open-label, multi-center Phase III trial is designed to evaluate the safety and efficacy of Baxter's adjuvant-free, whole-virus candidate vaccine. Vaccinations will begin in the first half of this year and results of the Phase III trial are scheduled to be available by the end of 2007.

"The results of the Phase I/II clinical trial suggested that this candidate vaccine may provide protection against divergent strains of virus, even at low dose levels without an adjuvant," said John Oxford, professor of Virology, The Queen Mary School of Medicine, London, United Kingdom. "The Phase III clinical trial is designed to confirm these findings and provide a solid measure of the vaccine's potential to protect a large number of people before and during a possible pandemic."

Baxter's candidate H5N1 vaccine is derived from H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure closely resembles the actual pathogen circulating in nature. The candidate vaccine induces an immune response (both cell and antibody mediated) that is similar to the body's defense against a natural virus, without the need to incorporate additional agents (adjuvants) to enhance immune response. It is manufactured using the company's proprietary vero cell technology, which produces high- yield vaccine more quickly than traditional approaches because it is not produced in eggs. Baxter's candidate vaccine is the first cell-
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/10/2014)... July 10, 2014 Integrated Silicon Solution, Inc. ... memory and analog IC solutions, today announced that it ... 24, 2014, at 7:00 a.m. Pacific Time (10:00 a.m. ... the fiscal 2014 third quarter ended June 30, 2014. ... dial 1-888-556-4997 before 6:50 a.m. Pacific time on July ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Inc. today announced the completion of subject dosing ... and bioavailability after administration of two proprietary formulations ... collaboration with the University of Minnesota and James ... experts in clinical research of the nasal delivery ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals ... 500 mg, the generic version of Novartis, Famvir® Tablets, a ... sales of approximately $196 million for the 12 months ending ... Currently, Mylan has 165 ANDAs pending FDA approval representing $98.5 ...
Cached Medicine Technology:Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam 2
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Denver, Colorado (PRWEB) July 10, 2014 ... countries will gather in Copenhagen this July 13-17 ... discoveries bringing the world closer to breakthroughs in ... is the world’s largest conference of its kind. ... program, AAIC serves as a catalyst for generating ...
(Date:7/10/2014)... July 10, 2014 CBPartners, a global ... has launched a new website. The redesigned site ... increased access to the firm’s thought pieces, blog posts, ... ideal platform to showcase our insights, capabilities, and to ... CBPartners’ Chief Executive Officer, Cyrus Chowdhury. “An enhanced ...
(Date:7/10/2014)... 10, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, ... over allegations that the woman’s hidden, aggressive leiomyosarcoma ... morcellator used during a routine laparoscopic supracervical hysterectomy ... Wolf Medical Instruments Corporation over its Wolf Power ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2
... ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem,(International) ... (NASDAQ: NRMX ; TSX: NRM), announces ... pursue the drug development program for its ... approval for,the treatment of Amyloid A (AA) ...
... VELCADE, melphalan and prednisone, reported a 32 percent complete remission rate ... ... CAMBRIDGE, Mass., March 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ... clinical trial of the combination therapy,VELCADE, melphalan and prednisone (VcMP) in ...
... notes due June 2008 ... expenses going forward Projects Zevalin(R) net ... 13 Seattle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MTA) ... twelve months ended December 31,2007., Recent Events, Announced ...
... Health Parity on Capitol Hill, WASHINGTON, March 12 ... Her Arms (TWLOHA) with the Mental Health Liaison,Group will ... Hill in,room B369 Rayburn House Office Building. It will ... Addiction Equity Act, an important,civil rights victory that begins ...
... Not Good Enough, WASHINGTON, March 12 Today, ... the,health-based National Ambient Air Quality Standard for ozone. We ... cannot. The standard announced,today, although an improvement, falls far ... are unable to celebrate half measures when the risks ...
... Award for ... Innovation in Healthcare Research, SACRAMENTO, Calif., March 12 ... ratios in California,hospitals revealed little impact on patient outcomes in ... the March 2008 issue of,Policy, Politics & Nursing Practice, a ...
Cached Medicine News:Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 2Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 4
... a Q-switched ruby laser system ... nm. High Performance Combined with ... combination of high performance and ... mode effectively destroys the (natural ...
... The NMP22 BladderChek Test is the only ... diagnosis of bladder cancer. The NMP22 BladderChek Test ... a single urine sample, that detects elevated levels ... small amounts of NMP22 protein in the urine. ...
... The NMP22® Test Kit is a quantitative ... NMP22 protein. Healthy individuals generally have very small ... the level of NMP22 protein is often elevated ... even at early stages of the disease. The ...
... cystometry and urethral pressure profilometry. The ... bladder to be filled while cystometry ... the catheter in the bladder for ... is standing or sitting. Supplied sterile ...
Medicine Products: